Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs

NYSE:UNH

UnitedHealth Group Inc (UNH)

400.26
-0.70 (0.17%)
as of Jun 18, 2026, 11:51:10 pm Market Open.
115 watching
0
TOP PICK
Healthcare gives you the combination of defence and offence. Largest managed care provider in the US. Medical insurance, pharma benefits, and healthcare services create a strong value proposition to its customers. This will lead to steadily and reliable sales. Last quarter, easily beat expectations and raised earnings guidance for the full year. Earnings growth should top 12% over the next few years. Yield is 1.26%, will grow over time. (Analysts’ price target is $579.00)
BUY
This one has many major components, and all are growing nicely. Growth expected at 15% this year and next. Small dividend, growing double digits. Ultimately, legislative is supportive of these companies. Great performer in a tough market. He'd buy here, great risk/reward. Though if the market recovers quickly, it may not outperform in the near term.
BUY
A go-to name, core holding. Because it's the largest in the US, it won't get caught offside by upcoming regulatory changes, the way a smaller company would. Pretty consistent grower at 15-20% per year.
BUY
Healthcare is his biggest sector. HC is seeing the classic shift to defensives as inflation peaks. Also, HC trades at only 18x while utilities and staples trade at 21x, so it's the cheapest defensive. He owns Pfizer, UNH and Regeneron. UNH's revenue and EPS beat recently. Healthcare has so many tailwinds, including again demographics. He likes preventative healthcare and UNH's position here. HC is fine in the late cycle. There's still to the upside here.
BUY
They report Friday and should have a great quarter, because Covid isn't as threatening as before. There is some cyclicality. If there are alot of layoffs, their numbers can weaken, but he doesn't see that now. Otherwise, keep buying, though he prefers the cheaper Humana.
PAST TOP PICK
(A Top Pick Jun 24/21, Up 27%) Adding to it. Is American's largest healthcare insurer and healthcare services. This synergy is great for customers. Also, healthcare offers defense as well as growth. Chart is trending upwards as the market goes down.
PAST TOP PICK
(A Top Pick Oct 20/20, Up 52%) Great business. Dominant player in managed care. GARP. Executing exceptionally well, consistent.
COMMENT
It beat two weeks ago, but it has struggled since then, because markets won't pay for future earnings. Not UNH's fault.
BUY
Healthcare has historically been a top sector after a yield curve inversion, when people get defensive. UNH dominates in commercial health, Medicare and Medicaid.
Unspecified
Has owned for many years. It is the best play in managed health care and helps payers and payees be more efficient and lower health care costs. Acquires and tucks in acquisitions. Highly innovative and very well managed. Maybe trading a bit on the rich side.
HOLD
An 800-pound gorilla. He'll continue to own it. Controlled costs by putting risk and responsibility on the actual providers of the healthcare services. Incentivizing to control costs at the local level. Short term, you may see costs spike due to pandemic-delayed visits. Medium-long term, you'll be fine.
BUY
It hit a new high today and he's long. It's reasonably valued. He targets at least $550.
HOLD
Likes it. EBV +6, means the stock price is pounding away. Stock could easily go to $650. Model price of $385.81, so it's too expensive by 22%. But any correction back to around $387, he'd buy.
SELL
Very good company, but not as good a stock because of valuation. He owns ANTM instead, trading about 6 multiple points less than UNH, with equally good growth metrics. Higher multiple stocks are selling off. Neither has supply chain issues.
TOP PICK
Clouds of macro risk. This one has consistently had visibility into its business. The most vertically integrated managed care company. Best in class GARP in healthcare. Administer a lot of Medicare and Medicaid. Bipartisan support for a lot of their programs. A consistent performer. Yield is 1.17%. (Analysts’ price target is $530.93)
Showing 46 to 60 of 190 entries